Clinical Trial · NCT05263466

Establishing Radiolabelled PSMA as a Target for Glioma Treatment

Overview

A study is being performed to observe whether a novel type of brain imaging using a technique called PET-MRI may provide useful information in the 'mapping' of adult primary brain tumours. It employs a radiolabelled molecule targeting a particular molecule called PSMA which is hypothesised to be a marker of aggression in primary brain tumours. 'Mapping' of the concentration and distribution of this molecule within brain tumours via PET-MRI may provide vital clinical information regarding the extent and timing of treatment.

Sponsor

King's College Hospital NHS Foundation Trust

Phase

N/A

Contacts

Thomas C Booth, PhD (CONTACT)

thomasbooth@nhs.net

07977509937

Thomas C Booth, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05263466

Drug / Compound

PSMA-11

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: HBED-CC

Eligibility

Inclusion

Referred for surgery (resection or biopsy) of presumed high grade primary brain tumour (based on imaging features of aggression e.g. perfusion imaging, diffusion restriction etc.). As standard, all patients will have had a full body CT and other investigations to rule out metastatic disease (this has a very high negative predictive value).

Exclusion

Contra-indication for MRI contrast
Inability to give consent
Patient already enrolled in a drug trial
Patient is pregnant or planning to become pregnant
Contra-indication for radiotracer